Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jul;254(1):295-304.
doi: 10.1111/imr.12073.

A global approach to HIV-1 vaccine development

Kathryn E Stephenson  1 , Dan H Barouch
Affiliations
Free PMC article
Review

A global approach to HIV-1 vaccine development

Kathryn E Stephenson et al. Immunol Rev. 2013 Jul.
Free PMC article

Abstract

A global human immunodeficiency virus-1 (HIV-1) vaccine will have to elicit immune responses capable of providing protection against a tremendous diversity of HIV-1 variants. In this review, we first describe the current state of the HIV-1 vaccine field, outlining the immune responses that are desired in a global HIV-1 vaccine. In particular, we emphasize the likely importance of Env-specific neutralizing and non-neutralizing antibodies for protection against HIV-1 acquisition and the likely importance of effector Gag-specific T lymphocytes for virologic control. We then highlight four strategies for developing a global HIV-1 vaccine. The first approach is to design specific vaccines for each geographic region that include antigens tailor-made to match local circulating HIV-1 strains. The second approach is to design a vaccine that will elicit Env-specific antibodies capable of broadly neutralizing all HIV-1 subtypes. The third approach is to design a vaccine that will elicit cellular immune responses that are focused on highly conserved HIV-1 sequences. The fourth approach is to design a vaccine to elicit highly diverse HIV-1-specific responses. Finally, we emphasize the importance of conducting clinical efficacy trials as the only way to determine which strategies will provide optimal protection against HIV-1 in humans.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immune responses targeted by a global HIV–1 vaccine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Walker BD, Ahmed R, Plotkin S. Use both arms to beat HIV. Nat Med. 2011;17:1194–1195. - PubMed
    1. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Ann Rev Med. 2012;63:95–111. - PMC - PubMed
    1. Rerks-Ngarm S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–2220. - PubMed
    1. Haynes BF, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366:1275–1286. - PMC - PubMed
    1. Bonsignori M, et al. HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. TIM. 2012;20:532–539. - PMC - PubMed

Publication types